Biolegend, 156603, TruStain FcX™ PLUS (anti-mouse CD16/32) Antibody, 50μg

CD16 is the low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. TruStain FcX™ PLUS is specific to the common epitope of CD16/CD32. It is useful for blocking non-specific binding of immunoglobulin to the Fc receptors and is more effective than TruStain FcX™.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Purity: The antibody was purified by affinity chromatography.
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration: 0.5 mg/ml
Storage & Handling: The CD16/32 antibody solution should be stored undiluted between 2°C and 8°C.
Application: FC - Quality tested
Recommended Usage: For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with TruStain FcX™ PLUS for 5-10 minutes, on ice, at 0.25 µg per 106 cells in a volume of 100 µl, prior to immunostaining. It is not necessary to wash the cells between the blocking and immunostaining steps.
Application Notes: Clone S17011E blocks both clone 93 and 2.4G2 also raised against mouse CD16/32
Product Citations: Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed Gonzalez C, et al. 2022. Life Sci. 309:121003. PubMed Egli J, et al. 2022. MAbs. 14:2143009. PubMed Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed Sang H, et al. 2023. Adv Clin Exp Med. 32:551. PubMed Zyla-Jackson K, et al. 2023. Front Neurol. 14:1113954. PubMed Chen Y, et al. 2023. J Nanobiotechnology. 21:98. PubMed Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed Zhou Y, et al. 2023. NPJ Regen Med. 8:23. PubMed Barisas DAG, et al. 2023. PLoS Biol. 21:e3001746. PubMed Lee K, et al. 2023. JCI Insight. 8:. PubMed Lin W, et al. 2023. Commun Biol. 6:447. PubMed Miyake K, et al. 2023. Nat Commun. 14:2694. PubMed Wang D, et al. 2023. Nat Commun. 14:2943. PubMed Arora S, et al. 2023. PLoS One. 18:e0286211. PubMed Oh J, et al. 2023. Nat Commun. 14:3278. PubMed Zhou J, et al. 2021. J Immunother Cancer. 9:. PubMed Driscoll J, et al. 2021. Curr Protoc. 1:e249. PubMed Bruno MEC, et al. 2022. J Cell Physiol. 237:706. PubMed Sweeney-Ambros AR, et al. 2022. J Orthop Res. 40:2843. PubMed Sugimoto M, et al. 2022. DNA Res. 29: . PubMed Wu J, et al. 2023. Bioact Mater. 20:259. PubMed Campisi L, et al. 2022. Nature. 606:945. PubMed Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed Li L, et al. 2022. J Exp Med. 219: . PubMed Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed Cagle LA, et al. 2023. Front Physiol. 13:1059686. PubMed Lin J, et al. 2023. Nat Commun. 14:224. PubMed Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed Chun J, et al. 2023. Cancers (Basel). 15: . PubMed Miller CL, et al. 2022. Cell Chem Biol. 29:451. PubMed Fu R, et al. 2020. Sci Rep. 10:1455. PubMed Bian L, et al. 2022. Front Immunol. 13:938598. PubMed Thomas AM, et al. 2022. J Neuroinflammation. 19:130. PubMed Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed Toomer G, et al. 2022. Viruses. 14:. PubMed Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed Music A, et al. 2022. Front Cell Dev Biol. 10:987148. PubMed Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed Westphal A, et al. 2017. J Exp Med. 214:227. PubMed Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed Chen X, et al. 2022. J Appl Oral Sci. 30:e20220316. PubMed Ikeda S, et al. 2022. Sci Rep. 12:11564. PubMed Thinard R, et al. 2022. Pharmaceutics. 14:. PubMed So EY, et al. 2021. Am J Physiol Cell Physiol. 321:C569. PubMed Wang JC, et al. 2022. Elife. 11:. PubMed Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed Dong L, et al. 2022. Cells. 11:. PubMed Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed Ejima R, et al. 2021. Nutrients. 13:. PubMed Guo S, et al. 2021. Sci Rep. 11:23745. PubMed Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed Galani IE, et al. 2022. STAR Protoc. 3:101151. PubMed Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed Montel-Hagen A, et al. 2022. Curr Protoc. 2:e403. PubMed Chen AF, et al. 2022. Nat Methods. 19:547. PubMed Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed Li N, et al. 2022. Nat Commun. 13:7281. PubMed Chen S, et al. 2022. iScience. 25:105176. PubMed Oya Y, et al. 2021. Front Immunol. 12:779709. PubMed Hobbs BE, et al. 2021. Pathogens. 10:. PubMed Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed Phan TS, et al. 2021. Sci Adv. 7:. PubMed Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed Van Winkle JA, et al. 2020. J Virol. 94:. PubMed Wang Y, et al. 2021. Nature. 599:308. PubMed Wang X, et al. 2021. Sci Transl Med. 13:. PubMed Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed Xu L, et al. 2022. Front Immunol. 13:841141. PubMed Matsuda A, et al. 2020. J Appl Toxicol. 40:706. PubMed Badgujar DC, et al. 2020. PLoS Pathog. 16:e1009016. PubMed Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
RRID: AB_2783137 (BioLegend Cat. No. 156603) AB_2783138 (BioLegend Cat. No. 156604)
Structure: Ig superfamily, 40-60 kD
Distribution: B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells
Ligand/Receptor: IgG
Cell Type: B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area: Immunology
Molecular Family: CD Molecules, Fc Receptors
Gene ID: 1413014131
UniProt: View information about CD16/32 on UniProt.org
Clone: S17011E
Regulatory Status: RUO
Other Names: CD16, CD32
Isotype: Rat IgG2b, κ